Landscape Capital Management L.L.C. acquired a new position in shares of uniQure N.V. (NASDAQ:QURE – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 83,838 shares of the biotechnology company’s stock, valued at approximately $2,026,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Privium Fund Management B.V. acquired a new position in uniQure in the 3rd quarter worth about $5,223,000. Pekin Hardy Strauss Inc. raised its position in uniQure by 63.3% in the third quarter. Pekin Hardy Strauss Inc. now owns 153,890 shares of the biotechnology company’s stock valued at $3,718,000 after purchasing an additional 59,640 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of uniQure during the third quarter valued at about $86,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of uniQure during the third quarter valued at about $310,000. Finally, Maxi Investments CY Ltd acquired a new stake in shares of uniQure during the third quarter valued at about $966,000. Institutional investors and hedge funds own 78.83% of the company’s stock.
Wall Street Analysts Forecast Growth
QURE has been the topic of several research reports. William Blair upgraded uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. Royal Bank Of Canada dropped their price objective on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating for the company in a report on Friday, October 2nd. UBS Group started coverage on shares of uniQure in a research report on Thursday, October 15th. They set a “buy” rating and a $48.00 target price on the stock. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, Barclays lowered shares of uniQure from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $60.00 to $28.00 in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.58.
Read Our Latest Report on uniQure
uniQure Price Performance
NASDAQ QURE opened at $20.30 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.52 and a current ratio of 11.52. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $51.72. The stock has a fifty day simple moving average of $28.04 and a 200 day simple moving average of $29.65.
uniQure (NASDAQ:QURE – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.17 million. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. As a group, analysts predict that uniQure N.V. will post -3.83 earnings per share for the current fiscal year.
uniQure Company Profile
uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.
Featured Articles
- Five stocks we like better than uniQure
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE – Free Report).
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
